CytomX Therapeutics Announces Business Update and Company Milestones for 2026

Core Insights - CytomX Therapeutics is advancing its clinical programs, particularly focusing on Varsetatug masetecan (Varseta-M) and CX-801, with significant milestones expected in 2026 [1][2][3] Clinical Program Updates - Varseta-M Phase 1 expansion data is on track for release in Q1 2026, with a combination study with bevacizumab in colorectal cancer (CRC) set to begin in Q1 2026 [1][4] - The total enrollment for the Varseta-M Phase 1 study is projected to reach approximately 100 patients by the planned update in Q1 2026 [6] - The company aims to align with the FDA in 2026 regarding a potential registrational study design for Varseta-M monotherapy in advanced CRC [6] - CX-801 Phase 1 study is ongoing, focusing on advanced melanoma, with monotherapy dose escalation having reached the fourth dose level [6] - Initial clinical data for CX-801 in combination with KEYTRUDA is anticipated by the end of 2026 [6] Strategic Focus - The company is committed to advancing Varseta-M towards a registrational trial in late-line CRC and aims to move it into earlier lines of treatment to address high unmet medical needs [2][3] - CytomX is leveraging its PROBODY therapeutic platform to progress a broader pipeline of therapeutics, including CX-801 [3][8] Upcoming Events - CytomX will present at the 44th Annual JP Morgan Healthcare Conference on January 14, 2026 [1][7]